South Africa has launched a national rollout of lenacapavir for HIV prevention during the second quarter of 2026, according to the WHO South Africa Quarter 2 Newsletter. The initiative represents a significant expansion of pre-exposure prophylaxis (PrEP) options in the country, which carries the world’s largest HIV burden. The rollout coincides with strengthened WHO regional support for disease prevention and health system resilience across the continent.
Key takeaways
- South Africa initiated national lenacapavir deployment for HIV prevention in April–June 2026, expanding long-acting PrEP access
- WHO South Africa supported concurrent hantavirus response operations and Ebola readiness during the quarter
- The country participated in the Global Forum of WHO Collaborating Centres in Lyon, deepening institutional partnerships for health system strengthening
WHO South Africa Quarter 2 Response Areas (April–June 2026)
Key programmatic domains supported by WHO regional office
Source: WHO South Africa, 2026 Q2 Newsletter | Georgian Medical Journal News
Lenacapavir Expansion Marks Shift in HIV Prevention Strategy
Lenacapavir, a first-in-class HIV maturation inhibitor developed by Gilead Sciences, offers a distinct pharmacological advantage over existing oral PrEP agents. According to the WHO South Africa Q2 Newsletter, the national rollout addresses adherence barriers that limit the effectiveness of daily oral regimens. South Africa’s uptake of this injectable option reflects global momentum toward long-acting HIV prevention modalities, particularly in sub-Saharan Africa, which accounted for approximately 70% of new HIV infections globally in 2025, according to UNAIDS epidemiological data.
The rollout follows regulatory approval pathways in South Africa and builds on country experience with other long-acting HIV interventions. Implementation includes community engagement and training of healthcare workers to support equitable access across provinces and population groups at highest risk.
WHO Regional Support Strengthens Multi-Threat Response Capacity
Beyond HIV prevention, the WHO South Africa Quarter 2 Newsletter documents concurrent technical assistance for hantavirus outbreak response and proactive Ebola virus disease readiness. Hantavirus cases have historically been confined to specific regions but remain a concern for surveillance systems and rapid response capacity in southern Africa. WHO’s support includes epidemiological investigation, laboratory capacity strengthening, and coordination with the South African National Institute for Communicable Diseases (NICD).
Ebola preparedness, which remains a standing priority across the WHO African Region, involves cross-border coordination mechanisms and pre-positioned response protocols. These efforts underscore the region’s shift toward proactive threat anticipation rather than reactive response, a principle central to the World Health Organization’s pandemic preparedness agenda.
Institutional Collaboration and Health Systems Resilience
South Africa’s participation in the Global Forum of WHO Collaborating Centres in Lyon during the second quarter positioned the country to deepen partnerships with international research and policy institutions. The WHO South Africa Q2 Newsletter emphasizes strengthened engagement with government ministries, national academic centres, civil society organizations, and community groups. This multi-stakeholder approach reflects WHO’s emphasis on building sustainable health systems capacity rather than vertical disease programming.
Regulatory systems development—including pharmacovigilance infrastructure and quality assurance frameworks—forms part of this systems-strengthening agenda. These foundational improvements support not only current HIV prevention initiatives but also future introduction of new health technologies and outbreak response tools.
South Africa’s lenacapavir rollout represents the integration of long-acting HIV prevention into a broader health systems strengthening agenda, supported by WHO technical assistance in disease surveillance, emergency preparedness, and institutional capacity development across the April–June 2026 quarter.
— WHO South Africa, Quarter 2 Newsletter (2026)
What this means
Frequently asked questions
How does lenacapavir differ from existing oral PrEP options?
Lenacapavir is administered as a long-acting injectable every six months (after an oral lead-in period), compared to daily oral tablets such as tenofovir/emtricitabine. This formulation may improve adherence in populations with barriers to daily medication routines, though both approaches require ongoing engagement and sexual health counselling.
Why did South Africa prioritise lenacapavir rollout in 2026?
South Africa carries the world’s largest HIV burden, with concentrated epidemics in key populations. Long-acting prevention options address documented adherence challenges in daily oral PrEP and align with global momentum toward injectable and implantable HIV prevention modalities recommended by international guidelines.
What is the connection between HIV prevention, hantavirus response, and Ebola readiness?
These initiatives reflect WHO’s integrated approach to health security: strengthening surveillance systems, laboratory capacity, and rapid response protocols that serve multiple pathogens. Enhanced preparedness for one threat builds foundational infrastructure that benefits response to other emerging infectious diseases.
As South Africa scales lenacapavir access and deepens regional partnerships through WHO Collaborating Centres, the country’s experience will provide critical data on implementation models, cost-effectiveness, and population-level impact in resource-constrained settings. Continued investment in health system infrastructure, community engagement, and equity-focused rollout strategies will determine whether new prevention tools translate into measurable reductions in HIV incidence across South Africa’s most vulnerable populations. The integration of HIV prevention innovation with broader preparedness and systems-strengthening work positions South Africa as a regional leader in health security and disease prevention.
Source: WHO South Africa Quarter 2 Newsletter (April–June 2026)
Was this article helpful?
Related Coverage
